AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02789371 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: the first pass is made with modified wet suction technique
Description: the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
Study NCT03797352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: To identify frailty and other potential health issues, and determine if Multicomponent exercise helps at-risk elderly to have better health outcomes.
Study NCT04664218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIPEC device
Description: To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places.
Study NCT02917746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
Study NCT02917746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Loop Excision of the Transformation Zone
Description: Patients in this group are treated with LLETZ.
Study NCT04894058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopic lithotripsy
Description: After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz.
Study NCT04894058 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ureteroscopic lithotripsy
Description: After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz.
Study NCT01189097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
Study NCT01189097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Administered intravenously (IV) over approximately one hour.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or intrathecally (IT).
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV.
Study NCT03164057 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ITMHA
Description: Given IT.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV over approximately 30 minutes.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase
Description: Given IV or intramuscularly (IM).
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given IV.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Given IV immediately before idarubicin administration.
Study NCT03164057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: The transplant protocol will depend on the patient's donor and transplant physician's preference.
Study NCT03164057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
Description: May be used in the event of an Erwinia asparaginase shortage. Given intramuscularly (IM).
Study NCT03176771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-5199
Description: MT-5199 40 mg capsules
Study NCT01099215 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PVS-10200
Description: PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
Study NCT04079751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Mechanical Alignment
Description: Hip-knee-ankle angle of 180° ± 3°.
Study NCT04079751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Alignment
Description: Restoring a patient's pre-diseased limb alignment
Study NCT02816775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
Study NCT03176771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MT-5199 placebo capsules
Study NCT02484677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
Study NCT02484677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxanes. Blood sampling for pharmacokinetic evaluation
Study NCT02484677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracile
Description: Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
Study NCT03927443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDP-133
Description: one drop
Study NCT03927443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumigan
Description: one drop
Study NCT00106002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
Study NCT02059707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT RS Suture Delivery Device
Description: LARIAT RS Suture Delivery Device
Study NCT02517281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study NCT04246463 — intervention group
Intervention type: DEVICE
Intervention: Thoracic
Description: Implant of a Relay stent graft system
Study NCT04246463 — intervention group
Intervention type: DEVICE
Intervention: Abdominal
Description: Implant with an Anaconda or Treo Stent graft system
Study NCT04246463 — intervention group
Intervention type: DEVICE
Intervention: Custom Device
Description: Implant of a Fenestrated device such as Fenestrated Anaconda or Fenestrated TREO, Relay Branch or other customised device
Study NCT04246463 — intervention group
Intervention type: DEVICE
Intervention: Illiac Artery
Description: Implant with an Anaconda Iliac leg only
Study NCT04382534 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Respiratory rehabilitation
Description: Health education and energy saving techniques, chest activity training, local lung dilation techniques, breathing training, airway clearance training, aerobic exercise, resistance training
Study NCT02816775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGRATH Videolaryngoscope
Description: After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
Study NCT02309931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: antiperistaltic side-to-side ileocecal anastomosis
Description: Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
Study NCT02309931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isoperistaltic side-to-side ileocecal anastomosis
Description: Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
Study NCT02822105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the H3N2 M2SR monovalent influenza vaccine
Description: The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.
Study NCT02822105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline
Study NCT01544036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perflutren
Description: Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
Study NCT00667511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NxStage System One
Description: Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
Study NCT00667511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NxStage System One
Description: Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
Study NCT02426697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl transmucosal
Description: Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
Study NCT02426697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
Study NCT04456686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: LY3016859 given IV.
Study NCT04456686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given IV.
Study NCT03409965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutronic Infini System
Description: A microneedle radiofrequency device
Study NCT03409965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutronic LaseMD System
Description: A fractional thulium laser device
Study NCT03670992 — intervention group
Intervention type: PROCEDURE
Intervention: duodenal-pancreatectomy
Description: surgical removal of metastatic repetitions in pancreas and/or other distal sites
Study NCT03857256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CP105F
Description: Natural Health Product
Study NCT03857256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet manufactured to mimic the CP105F beta-glucan
Study NCT01201863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgel (Testosterone Gel)
Description: 2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
Study NCT01201863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: 2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
Study NCT04103840 — intervention group
Intervention type: OTHER
Intervention: Testing stool mycobiota
Description: Both cohorts of SAH and their family controls will be tested for fecal mycobiota
Study NCT04207671 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Complete omission of chest tube
Description: No chest tube implacement
Study NCT04207671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Improved drainage strategy
Description: A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
Study NCT04337632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection+carboplatin
Description: Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.
Study NCT04337632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel +carboplatin
Description: paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.
Study NCT03980119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HITSystem 3.0
Description: The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
Study NCT03651804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of the medial branch nerves
Description: A radiofrequency ablation (RFA) is a procedure in which a heat lesion via a needle is created on the nerve that transmits the pain signal in order to interrupt the brain to interrupt the painful signal to the brain. We will target the medial branch nerves.
Study NCT03651804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs
Description: Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
Study NCT03651804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonates
Description: A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
Study NCT03651804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
Study NCT03651804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical Therapy.
Study NCT03651804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
Study NCT03118050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Supervised resistance exercise training, 3 times a week for 3 months
Study NCT03118050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Bed rest for 5 days, followed by standard rehabilitation for 2 days
Study NCT01464372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Field Stimulation Device
Description: Treatment with Electrical Field Stimulation Device
Study NCT01464372 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Nerve Stimulation Device
Description: Use of the sham device
Study NCT01788462 — intervention group
Intervention type: DRUG
Intervention: Tesamorelin (Egrifta)
Description: We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
Study NCT02070939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06260414
Description: Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
Study NCT02070939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
Study NCT02070939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06260414
Description: Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
Study NCT03118050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Description: Intensive weight bearing PT, daily, during bed rest
Study NCT02915835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
Study NCT02915835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
Study NCT02070939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
Study NCT02070939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06260414
Description: Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
Study NCT02070939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
Study NCT01802151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. subtilis R0179
Description: B. subtilis R0179 for a period of 4 weeks. One capsule per day.
Study NCT02123641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heavy resistance training
Description: Supervised heavy resistance training three times weekly for 52 weeks.
Study NCT02123641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity training
Description: Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
Study NCT02123641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No training
Study NCT02426801 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
Study NCT02426801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
Study NCT02426801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application for asthma adherence
Description: Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
Study NCT03426345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected subcutaneously twice daily.